Nektar Therapeutics announced that new phase I clinical data for Nektar’s lead immuno-oncology agent, NKTR-214, were presented at the SITC 2016 Annual Meeting.
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
